Other languages Disc Medicine, Inc.

Equities

IRON

US2546041011

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
27.55 ^USD	+3.88%		-3.97%	-52.30%

04-08	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT
04-02	Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	04-01
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	04-01
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	04-01
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	02-26
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	02-26
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	02-20
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	02-20
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	02-09
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	02-09
Disc Medicine, Inc. Announces Promotion of Jonathan Yu to Chief Operating Officer	02-07
Disc Medicine Insider Sold Shares Worth $6,934,125, According to a Recent SEC Filing	01-25
Disc Medicine Insider Sold Shares Worth $1,280,000, According to a Recent SEC Filing	01-12
Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board	12-20
Disc Medicine Insider Sold Shares Worth $2,118,239, According to a Recent SEC Filing	12-14
Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology Annual Meeting	12-11
Disc Medicine Insider Sold Shares Worth $248,012, According to a Recent SEC Filing	11-15
Disc Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Disc Medicine's Finance Chief Joanne Bryce to Depart	23-10-23
Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers	23-10-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Disc Medicine, Inc.

Equities

IRON

US2546041011

Other languages

Filters